Matthijs Van Meerveld, Associate Vice President, Global Head of Patient Advocacy and Policy at Menarini Stemline, shared an update from Alamo Breast Cancer Foundation, on LinkedIn, adding:
“Insightful discussion on decision-making around monotherapy and combination therapy in breast cancer, with Mary Jimenez (Director, Alamo Advocate Program) and Dr Neil Iyengar (Co-Director, Breast Medical Oncology, Director, Cancer Survivorship Services, Winship Cancer Institute at Emory University).
Menarini Stemline is a proud supporter of the Alamo Advocate Program, presented by the Alamo Breast Cancer Foundation, and the San Antonio Breast Cancer Symposium.”
Quoting Alamo Breast Cancer Foundation:
“Calling all advocates! Tune into our 2026 Advocate Chats.
Here is the first one in the 2026 series, ‘From Guidelines to Bedside: Decision-Making in Monotherapy and Combination Breast Cancer Treatment’, featuring Neil Iyengar, Co-Director, Breast Medical Oncology, Director, Cancer Survivorship Services Associate Professor of Hematology and Medical Oncology Winship Cancer Institute of Emory University, and Mary Jimenez, Director Alamo Advocate Program, Chair Mays Cancer Center at UT Health San Antonio COE Advisory Board, Co-Founder iConsult Group.
Alamo Advocate Program 2026 Live and Virtual Event registration is now open.”
You might be interested in:
